AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12648985 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy with propranolol (with or without isosorbide‐5‐mononitrate [ISMN])
Number of subjects: 136
Study 12648985 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with ISMN for non-responders
Number of subjects: 136
Study 10848909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 688
Study 10848909 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 688
Study 10848909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688
Study 8812029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially random configurations
Number of subjects: 0
Study 8812029 — intervention group
Group type: COMPARATOR
Intervention: Linear arrays
Number of subjects: 0
Study 8812029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense arrangement of items
Number of subjects: 0
Study 8812029 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiating objects by color
Number of subjects: 0
Study 1582601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 3 mg
Number of subjects: 19
Study 1582601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide 5 ng/kg
Number of subjects: 19
Study 1582601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2933261 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m1099 (1-deoxynojirimycin derivative)
Number of subjects: 12
Study 2933261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30982943 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE intervention (integrated Body Project and Healthy Weight Intervention)
Number of subjects: 27
Study 31046722 — intervention group
Group type: EXPERIMENTAL
Intervention: PowerPoint‐oriented health education intervention
Number of subjects: 1675
Study 31046722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1675
Study 28146243 — intervention group
Group type: EXPERIMENTAL
Intervention: R-E group (smoking-related memory retrieval followed by extinction training)
Number of subjects: 88
Study 28146243 — intervention group
Group type: EXPERIMENTAL
Intervention: R-E group
Number of subjects: 88
Study 28146243 — intervention group
Group type: COMPARATOR
Intervention: NR-E group (nonsmoking-related retrieval followed by extinction training)
Number of subjects: 88
Study 24510801 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned electrical stimulation applied to the S2 or S3 dermatome
Number of subjects: 10
Study 24510801 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 10
Study 23036478 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 patch (highest dose)
Number of subjects: 116
Study 23036478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest-dose patch
Number of subjects: 116
Study 23036478 — intervention group
Group type: EXPERIMENTAL
Intervention: All three patches
Number of subjects: 116
Study 20182454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS with RAS blockade
Number of subjects: 7665
Study 20182454 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 7665
Study 19916825 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program led by fitness instructors
Number of subjects: 4
Study 19916825 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program
Number of subjects: 4
Study 16491144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 290
Study 16491144 — intervention group
Group type: COMPARATOR
Intervention: Vertical compaction
Number of subjects: 290
Study 15328674 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational handout monthly for 2 months
Number of subjects: 0
Study 15328674 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one educational session with a physician or nurse practitioner
Number of subjects: 0
Study 15328674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 11732287 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 30
Study 11732287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9150029 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating-gait orthoses (RGOs)
Number of subjects: 8
Study 9150029 — intervention group
Group type: COMPARATOR
Intervention: Hip-knee-ankle-foot orthoses (HKAFOs)
Number of subjects: 8
Study 7910836 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated HIV-1 immunogen in incomplete Freund's adjuvant (IFA)
Number of subjects: 103
Study 7910836 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant alone (Control)
Number of subjects: 103
Study 3109017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil, 35 micrograms twice daily
Number of subjects: 106
Study 3109017 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 400 mg twice daily
Number of subjects: 106
Study 3109017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (nonsmokers)
Number of subjects: 106
Study 3109017 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (nonsmokers)
Number of subjects: 106
Study 3109017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (smokers)
Number of subjects: 106
Study 3109017 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (smokers)
Number of subjects: 106
Study 3109017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 106
Study 3109017 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 106
Study 1972218 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral nicotinamide daily for three weeks
Number of subjects: 29
Study 1972218 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for three weeks
Number of subjects: 29
Study 31274492 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic Nerve Infiltration with 10 mL of 0.2% Ropivacaine
Number of subjects: 126
Study 31274492 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol Infusion with 20mg/kg
Number of subjects: 126
Study 28033193 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 29
Study 28033193 — intervention group
Group type: COMPARATOR
Intervention: Iliac cancellous bone and marrow grafts without PRP (Control)
Number of subjects: 29
Study 25873635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every four weeks (120/Q4W)
Number of subjects: 1041
Study 25873635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 90 mg every two weeks (90/Q2W)
Number of subjects: 1041
Study 25873635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study 25873635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab groups
Number of subjects: 1041
Study 23567397 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day, flexible dosing)
Number of subjects: 338
Study 23567397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 23567397 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 338
Study 21564464 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 18
Study 21564464 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 18
Study 19450647 — intervention group
Group type: EXPERIMENTAL
Intervention: DCs infected with CP-HIV+KLH (arm A, n=14)
Number of subjects: 29
Study 17006279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine, trivalent (CAIV-T)
Number of subjects: 2187
Study 17006279 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 2187
Study 14556922 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 1021
Study 14556922 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1021
Study 11543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.35 g/kg)
Number of subjects: 0
Study 11543984 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose Delta(9)-tetrahydrocannabinol (THC) with ethanol (0.7 g/kg)
Number of subjects: 0
Study 11543984 — intervention group
Group type: COMPARATOR
Intervention: Placebo THC with ethanol (placebo)
Number of subjects: 0
Study 11543984 — intervention group
Group type: COMPARATOR
Intervention: Placebo THC with placebo ethanol
Number of subjects: 0
Study 9631978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination of bisoprolol/hydrochlorothiazide
Number of subjects: 0
Study 9631978 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 9631978 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 8161715 — intervention group
Group type: COMPARATOR
Intervention: Dilapress 120 mg tablets (twice-daily dosing)
Number of subjects: 0
Study 8161715 — intervention group
Group type: COMPARATOR
Intervention: Dilapress 240 mg tablets (once-daily treatment)
Number of subjects: 0
Study 8161715 — intervention group
Group type: COMPARATOR
Intervention: Cardizem CD
Number of subjects: 0
Study 3360860 — intervention group
Group type: EXPERIMENTAL
Intervention: Teonova (theophylline) 600 mg administered 10 min before breakfast
Number of subjects: 20
Study 3360860 — intervention group
Group type: COMPARATOR
Intervention: Teonova (theophylline) 600 mg administered 60 min after breakfast
Number of subjects: 20
Study 3360860 — intervention group
Group type: EXPERIMENTAL
Intervention: Teonova (theophylline) 600 mg administered 10 min before dinner
Number of subjects: 20
Study 3360860 — intervention group
Group type: COMPARATOR
Intervention: Teonova (theophylline) 600 mg administered 60 min after dinner
Number of subjects: 20
Study 29546346 — intervention group
Group type: EXPERIMENTAL
Intervention: Afebrile P. falciparum infections detected with RDTs
Number of subjects: 32
Study 26698689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 855
Study 24512252 — intervention group
Group type: EXPERIMENTAL
Intervention: 17P (250mg weekly injections)
Number of subjects: 45
Study 24512252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23738949 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait analysis report
Number of subjects: 39
Study 23738949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gait analysis report)
Number of subjects: 39
Study 20047620 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan
Number of subjects: 183
Study 20047620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 18713550 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GSVL)
Number of subjects: 76
Study 18713550 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDL)
Number of subjects: 76
Study 16410271 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping of the dialysate outlet line
Number of subjects: 20
Study 16410271 — intervention group
Group type: COMPARATOR
Intervention: No clamping of the dialysate outlet line
Number of subjects: 20
Study 12562449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 4 weeks
Number of subjects: 68
Study 12562449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11163746 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 11163746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0
Study 11163746 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-infarction care
Number of subjects: 0
Study 9159565 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (Ang II) infusion
Number of subjects: 10
Study 8203983 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 75
Study 8203983 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 75
Study 3307889 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz ray therapy (3 Gy applied on six occasions at intervals of 1 week)
Number of subjects: 24
Study 3307889 — intervention group
Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 24
Study 31072186 — intervention group
Group type: EXPERIMENTAL
Intervention: Trium CTG Online® computer analysis
Number of subjects: 26
Study 31072186 — intervention group
Group type: COMPARATOR
Intervention: Obstetricians' interpretation
Number of subjects: 26
Study 30765433 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 291
Study 30765433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 291
Study 28215661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored help-seeking advice (screening group)
Number of subjects: 10190
Study 28215661 — intervention group
Group type: COMPARATOR
Intervention: General mental health advice (control group)
Number of subjects: 10190
Study 26080572 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinghouyan lozenge for 5 days
Number of subjects: 144
Study 26080572 — intervention group
Group type: COMPARATOR
Intervention: Qinghouyan oral Liquid for 5 days
Number of subjects: 144
Study 26080572 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinghouyan lozenge
Number of subjects: 144
Study 26080572 — intervention group
Group type: COMPARATOR
Intervention: Qinghouyan oral Liquid
Number of subjects: 144
Study 23850914 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 20 to 39 years
Number of subjects: 5
Study 23850914 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 40 to 49 years
Number of subjects: 5
Study 23850914 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 50 to 59 years
Number of subjects: 5
Study 23850914 — intervention group
Group type: COMPARATOR
Intervention: Age group 60 to 69 years
Number of subjects: 5
Study 23850914 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group ≥70 years
Number of subjects: 5
Study 23850914 — intervention group
Group type: COMPARATOR
Intervention: Youngest group (20 to 39 years) vs. referent group (60 to 69 years)
Number of subjects: 5
Study 21388992 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 0
Study 21388992 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 19553405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (CJ) 240 mL once daily for 2 weeks
Number of subjects: 30
Study 19553405 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage 240 mL once daily for 2 weeks
Number of subjects: 30
Study 19553405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (CJ)
Number of subjects: 30
Study 17201539 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit contemplation of cancer
Number of subjects: 5
Study 17201539 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about cancer under high cognitive load
Number of subjects: 5
Study 17201539 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal primes of the word cancer
Number of subjects: 5
Study 17201539 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived vulnerability to cancer
Number of subjects: 5
Study 17201539 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load after cancer salience
Number of subjects: 5
Study 15113993 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise supplemented with an 8-week class-based exercise programme
Number of subjects: 214
Study 15113993 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise alone
Number of subjects: 214
Study 11133601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.75 mg/kg preservative‐free S(+)‐ketamine and 0.75 mg/kg midazolam
Number of subjects: 62
Study 11133601 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg midazolam
Number of subjects: 62
Study 11133601 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg preservative‐free S(+)‐ketamine
Number of subjects: 62
Study 9695971 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 microg/kg/d MGDF
Number of subjects: 8
Study 9695971 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 8
Study 9695971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 5.0 microg/kg/d MGDF
Number of subjects: 8
Study 9695971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus MGDF
Number of subjects: 8
Study 8205826 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding
Number of subjects: 95
Study 8205826 — intervention group
Group type: COMPARATOR
Intervention: Topical antimicrobial prophylaxis and sucralfate (1 g/6 hrs)
Number of subjects: 95
Study 8205826 — intervention group
Group type: COMPARATOR
Intervention: Gastric pH-increasing stress ulcer prophylaxis
Number of subjects: 95
Study 8205826 — intervention group
Group type: COMPARATOR
Intervention: No enteral feeding
Number of subjects: 95
Study 2530922 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 26
Study 2530922 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 26
Study 2530922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 26
Study 1097878 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (3 X 10 and 20 mug)
Number of subjects: 96
Study 1097878 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (3 X 2.0 mg)
Number of subjects: 96
Study 1097878 — intervention group
Group type: COMPARATOR
Intervention: Terbutalin (3 X 2.5 mg)
Number of subjects: 96
Study 31629371 — intervention group
Group type: EXPERIMENTAL
Intervention: Abivertinib metabolites M7 and MII-6 quantification method using LC-MS/MS
Number of subjects: 0
Study 31629371 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability assessments of M7 and MII-6
Number of subjects: 0
Study 30582281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prolonged-release tacrolimus
Number of subjects: 0
Study 30582281 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prolonged-release tacrolimus
Number of subjects: 0
Study 30582281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prolonged-release tacrolimus + ACEi/ARB
Number of subjects: 0
Study 30582281 — intervention group
Group type: COMPARATOR
Intervention: Low-dose prolonged-release tacrolimus + OAHT
Number of subjects: 0
Study 30582281 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi/ARB
Number of subjects: 0
Study 30582281 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 27906549 — intervention group
Group type: EXPERIMENTAL
Intervention: HFHC meal with 30 g of insoluble dietary fiber
Number of subjects: 10
Study 27906549 — intervention group
Group type: COMPARATOR
Intervention: HFHC meal alone
Number of subjects: 10
Study 25913272 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 with booster dose (R3R group)
Number of subjects: 15459
Study 25913272 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 with comparator vaccine (R3C group)
Number of subjects: 15459
Study 25913272 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine (C3C group)
Number of subjects: 15459
Study 23632396 — intervention group
Group type: EXPERIMENTAL
Intervention: FDT Matrix 30/2 examination with best refractive correction
Number of subjects: 48
Study 23632396 — intervention group
Group type: COMPARATOR
Intervention: FDT Matrix 30/2 examination without refractive correction
Number of subjects: 48
Study 21323490 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet cognitive behaviour therapy (CBT)
Number of subjects: 75
Study 21323490 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive behaviour therapy (CBT)
Number of subjects: 75
Study 19776082 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery dissection and application of a collagen patch coated with human fibrinogen and thrombin (TachoSil)
Number of subjects: 60
Study 19776082 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) with stapling device
Number of subjects: 60
Study 16924989 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal pit/fissure sealant
Number of subjects: 96
Study 16924989 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraFinish surface sealant
Number of subjects: 96
Study 16924989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sealant applied)
Number of subjects: 96
Study 16924989 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond MultiPurpose adhesive
Number of subjects: 96
Study 14742372 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream after ultrasound pretreatment
Number of subjects: 42
Study 14742372 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream application for 5 min
Number of subjects: 42
Study 14742372 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream application for 10 min
Number of subjects: 42
Study 14742372 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream application for 15 min
Number of subjects: 42
Study 14742372 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream application for 60 min without ultrasound pretreatment
Number of subjects: 42
Study 11328297 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Number of subjects: 145
Study 9715644 — intervention group
Group type: COMPARATOR
Intervention: BiPAP-S/T
Number of subjects: 15
Study 9715644 — intervention group
Group type: COMPARATOR
Intervention: VPAP-S/T
Number of subjects: 15
Study 9148253 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hydrogel (T-Gel 0.1%)
Number of subjects: 20
Study 9148253 — intervention group
Group type: COMPARATOR
Intervention: Aqueous timolol 0.5%
Number of subjects: 20
Study 9148253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2255026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 155
Study 2255026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 6991107 — intervention group
Group type: EXPERIMENTAL
Intervention: DA plus cis‐dichlorodiammineplatinum(II) (DAP)
Number of subjects: 41
Study 6991107 — intervention group
Group type: COMPARATOR
Intervention: Dianhydrogalactitol plus Adriamycin (DA)
Number of subjects: 41